ProCE Banner Activity

SYMPATICO: Phase III Trial of Ibrutinib + Venetoclax vs Ibrutinib + Placebo for Patients With R/R Mantle Cell Lymphoma

Conference Coverage

Compared with ibrutinib monotherapy, the combination of venetoclax and ibrutinib significantly improved PFS with no unexpected toxicities for patients with R/R MCL in this randomized, placebo-controlled, double-blind phase III trial.

Released: December 14, 2023


Provided by

Provided by Clinical Care Options, LLC

ProCE Banner


Supported by educational grants from AbbVie Inc., AstraZeneca, Daiichi Sankyo, Inc., Merck Sharp & Dohme LLC, Novartis Pharmaceuticals Corporation, Regeneron Pharmaceuticals, Inc, and Seagen Inc.

AbbVie Inc.


Daiichi Sankyo, Inc.

Merck Sharp & Dohme, LLC

Novartis Pharmaceuticals Corporation

Regeneron Pharmaceuticals, Inc

Seagen Inc.